Hercules, CA — November 5, 2012 — Bio-Rad Laboratories, Inc. today announced the availability of two new 96-well Hard-Shell plates for PCR and real-time PCR (qPCR). These plates add to Bio-Rad’s Hard-Shell plate offering, expanding the availability of Hard-Shell plate technology for a variety of PCR instruments. The Hard-Shell low-profile semi-skirted PCR plate. is compatible with multiple instruments including the Applied Biosystems 7500 Fast and ViiA 7 real-time PCR systems. The Hard-Shell 96-well 480 PCR plate. is designed and optimized specifically for the Roche LightCycler 480 System.
The patented Hard-Shell technology prevents plate warping that often occurs during thermal cycling. The two-component Hard-Shell microplate design incorporates a polycarbonate shell with superior stability and flatness, which is ideal for heat sealing methods. The extremely uniform wells made from virgin polypropylene help reduce well-to-well variability in real-time PCR experiments. In addition, black alphanumeric lettering facilitates sample loading by making it easier to identify different wells in your PCR plate.
PCR plastics hold samples throughout the entire PCR workflow and are critical for successful experiments. The new 96-well Hard-Shell plates have undergone extensive quality control and validation, providing researchers with confidence in their plastics.
For further details about the Hard-Shell 96-well plates, including a complete list of instrument compatibility, please visit here.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit here.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Richard Kurtz
Bio-Rad
510-741-5638
Richard_Kurtz@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com
